• GNA Biosolutions GmbH
  • Am Klopferspitz 19
  • 82152 Planegg/Martinsried
  • Germany
  • Phone: +49 (0)89/99 82 07 180
  • Fax: +49 (0)89/99 82 07 188
  • moc.oib-ang@ofni

GNA Biosolutions

v.l.n.r.: Dr. Lars Ullerich, CBO; Dr. Joachim Stehr, CSO; Dr. Federico Buersgens, CEO

About GNA Biosolutions

GNA was founded in 2010 and currently consists of a multidisciplinary team of 44 people. GNA’s technology, called Pulse Controlled Amplification (PCA), is based on the molecular gold standard technology, the polymerase chain reaction (PCR), but works much faster (minutes instead of hours) and can be used to produce small, portable, energy-efficient instruments. Unlike traditional PCR, PCA enables the production of systems that can provide a diagnosis close to the patient outside the laboratory. The company is currently focusing on the development of a rapid diagnostic system and assays to diagnose Covid-19, which can diagnose up to eight patient samples simultaneously and can be used in many environments, including airports and other transit points.

What is your motivation?

Our goal is to make molecular testing possible for everyone, everywhere. GNA Biosolutions uses a novel proprietary technology to develop systems for molecular diagnostics. Molecular diagnostics is the most sensitive and reliable approach to diagnosing Covid-19. Our multidisciplinary team of biologists, engineers, physicists, and developers has created a powerful new technology that revolutionizes molecular testing. Our innovations aim to improve patient care, prevent harm, save lives, and enable better molecular diagnostics and DNA analysis. We achieve this by maintaining the effectiveness of our QMS, by complying with applicable quality, safety and regulatory standards, and by striving for excellence in everything we do.

“For GNA, the IZB offers with its location and premises ideal conditions for the research and development of our technology.”

Dr. Lars Ullerich, CBO; Dr. Joachim Stehr, CSO;
Dr. Federico Buersgens, CEO

GNA was founded in 2010 and currently consists of a multidisciplinary team of 44 people. GNA’s technology, called Pulse Controlled Amplification (PCA), is based on the molecular gold standard technology, the polymerase chain reaction (PCR), but works much faster (minutes instead of hours) and can be used to produce small, portable, energy-efficient instruments. Unlike traditional PCR, PCA enables the production of systems that can provide a diagnosis close to the patient outside the laboratory. The company is currently focusing on the development of a rapid diagnostic system and assays to diagnose Covid-19, which can diagnose up to eight patient samples simultaneously and can be used in many environments, including airports and other transit points.